Discover what's new.

Access the latest news, business developments, company updates, industry trends, events and more.

| By Kelley Gipson

Enko raises overall capital to date to $150 million

Enko has raised additional funding, bringing the company’s overall capital raised to date to $150 million. Enko will use the new funds to advance the company’s...

| By Kelley Gipson

The Roundup – February 9, 2023

View this email in your browser February 9, 2023 Senator Chris Murphy recently announced Modifi Bio as “Innovator of the Month” for January. Murphy said, “Modifi Bio...

| By Kelley Gipson

ConnCAT launches paid biopharma training program

ConnCAT – one of the states leading job training and skill-building organizations – is teaming up with Yale to launch a program to train New Haven...

| By Kelley Gipson

Connecticut Innovations Launches Future Fund

Connecticut Innovations, the state’s strategic venture capital arm, has launched a new fund committed to investing in early-stage companies, with an emphasis on underrepresented founders. The...

| By Kelley Gipson

Career Newsletter – February 7, 2023

View this email in your browser February 7, 2023 Arvinas  Summer Internship, Neuroscience New Haven Summer Internship, Drug Discovery, Artificial Intelligence New Haven Summer Internship,...

| By Kelley Gipson

The Roundup – February 2, 2023

View this email in your browser February 2, 2023 Connecticut Innovations (CI) announced that it invested $10 million in early-stage companies and fund of funds during the...

| By Kelley Gipson

FDA accepts NDA re Jardiance® for kidney disease

Boehringer Ingelheim and Eli Lilly and Company announced that the FDA has accepted a supplemental New Drug Application for Jardiance® (empagliflozin) tablets. The tablets are being investigated as...

| By Kelley Gipson

Individualized cancer treatment software from Yale

In an effort to practice precision medicine — a medical movement to develop specific treatments for individual patients — scientists created software to quantify and...

| By Kelley Gipson

BioXcel reports promising results re prostate cancer

BioXcel Therapeutics reports promising top-line data from its Phase 2 trial of BXCL701, the Company’s investigational, oral innate immune activator, in combination with KEYTRUDA® (pembrolizumab) in small...